BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

CEO

Mr. Kenneth Mulvany

Employees

180

Country

Luxembourg

ISIN

LU2355630455

Listings

0 Comments

Share your thoughts

FAQ

What is Benevolent AI stock price today?▼

The current price of BAI.AS is €0.08 EUR — it has decreased by -14.74% in the past 24 hours. Watch Benevolent AI stock price performance more closely on the chart.

What is Benevolent AI stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Benevolent AI stocks are traded under the ticker BAI.AS.

What is Benevolent AI revenue for the last year?▼

Benevolent AI revenue for the last year amounts to 7.33M EUR.

What is Benevolent AI net income for the last year?▼

BAI.AS net income for the last year is -63.32M EUR.

How many employees does Benevolent AI have?▼

As of April 29, 2026, the company has 180 employees.

In which sector is Benevolent AI located?▼

Benevolent AI operates in the Health & Wellness sector.

When did Benevolent AI complete a stock split?▼

Benevolent AI has not had any recent stock splits.

Where is Benevolent AI headquartered?▼

Benevolent AI is headquartered in London, Luxembourg.